Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (2.360.978 €): Koordination von Forschung und Evidenz für Medizinprodukte Hor 22.01.2021 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Text

Koordination von Forschung und Evidenz für Medizinprodukte

CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices (Work Package 1), recommend how new trial designs can contribute (Work Package 2), and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice (Work Package 3). Multidisciplinary workshops will propose a hierarchy of levels of evidence from clinical investigations; educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe; and an ethics charter for medical device innovation (Work Package 4). Industry participation will be invited. Specific CORE–MD tasks will advise on optimal statistical methods, the utility of patient-reported outcomes, the conduct of registry trials, clinical criteria for evaluating artificial intelligence as a medical device, and how to evaluate medical devices used in children. The essential principles of medical device trials will be considered jointly with the Good Clinical Trials Collaborative. Links between CORE–MD partners will catalyse sustainable networks for research. The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe. Final recommendations will be submitted to the Working Group on Clinical Investigation and Evaluation of the European Commission to be considered when developing EU guidance or common specifications.


Geförderte Unternehmen:

Firmenname Förderungssumme
Academisch Ziekenhuis Leiden 367.895 €
Biomedical Alliance in Europe 52.024 €
Efort 199.169 €
European Academy OF Paediatrics 58.563 €
Forum des Patients Europeens 57.650 €
Fundacion Publica Andaluza Progreso y Salud M.P 48.775 €
Goeteborgs Universitet 48.249 €
Health Products Regulatory Authority 50.000 €
HTA Austria - Austrian Institute FOR Health Technology Assessment GmbH 52.969 €
Insel Gruppe AG 106.400 €
Istituto Superiore Di Sanita 64.428 €
Katholieke Universiteit Leuven 100.026 €
Laegemiddelstyrelsen 21.250 €
Politecnico Di Milano 108.750 €
Region Uppsala 92.220 €
Rijksinstituut Voor Volksgezondheid EN Milieu (Rivm) 86.605 €
Royal College of Surgeons in Ireland 109.900 €
SE de Cardiologie 448.140 €
The Chancellor, Masters and Scholars of the University of Oxford 135.566 €
THE European Association Medical Devices-Notified Bodies 39.000 €
Umit Tirol - Private Universitat FUR Gesundheitswissenschaften UND Technologie GmbH 103.400 €
Universidad de Granada 0,00 €
Urzad Rejestracji Produktow Leczniczych, Wyrobow Medycznych i Produktow Biobojczych 10.000,00 €

Quelle: https://cordis.europa.eu/project/id/965246

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.